As the saying goes – “a rising tide lifts all boats”, and we would expect that universal implementation of GMPs would buoy product quality among those…
In Conversation
The reluctance to invest in phase one trials is multifaceted. One aspect is the fear of generic molecule development in India, even though the regulatory environment…
An alarming statistic is that half of the individuals with diabetes remain undiagnosed. Moreover, Indians tend to develop diabetes a decade earlier than their Western counterparts,…
India contributes nearly 90 percent of the global production of castor oil, and we export our product to almost every corner of the world
One of the prominent challenges the country is facing is the over-dependency on China for APIs. As a country we want to avoid this dependency and…
India is a market with great potential. However, it's important to recognize that the market is price-sensitive, requiring patience and a strategic approach
Regulatory intervention in India is more rigorous than ever before
India's thriving ecosystem, coupled with the increasing demand for the right partners and investments, makes it an ideal destination for those looking to be part of…
In terms of innovation, the [Indian pharmaceutical] landscape is evolving, but not at a pace that matches global leaders
Practice venturing into areas that make you uncomfortable; these are the assignments that give us maximum learning and personal growth. If you have the aspiration, raise…
Our focus revolves around three key aspects: API, international formulation exports, and the domestic market... targeting a compounded annual growth rate of 25 to 30 percent…
We are steadily transforming from a relatively smaller player in generics and early-phase clinical studies to a broader and more relevant Contract Research Organization for our…
